CircRNA Sequencing Service Market 2026-2032: The USD 1.07 Billion Circular RNA Frontier Unlocking Stable Biomarkers for Precision Medicine
Global Leading Market Research Publisher QYResearch announces the release of its latest report ”CircRNA Sequencing Service – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global CircRNA Sequencing Service market, including market size, share, demand, industry development status, and forecasts for the next few years.
For translational researchers who recognize that linear RNA biomarkers degrade within minutes in circulation—rendering them unreliable for clinical diagnostics—and for pharmaceutical executives building next-generation RNA therapeutic platforms who understand that circular RNAs resist exonuclease degradation and persist in biological fluids for extended periods, circRNA sequencing has emerged as a strategically essential discovery and validation tool. The global market for CircRNA Sequencing Service was estimated to be worth USD 682 million in 2025 and is projected to reach USD 1,068 million by 2032, growing at a compound annual growth rate (CAGR) of 6.7% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6083849/circrna-sequencing-service
Market Size and the Structural Stability Advantage
The market’s valuation of USD 682 million in 2025 reflects the specialized nature of circRNA sequencing, which requires additional enzymatic pre-treatment steps—specifically RNase R digestion to remove linear RNA species—distinguishing it from standard RNA sequencing services. The projected expansion to USD 1,068 million by 2032 at 6.7% CAGR represents sustained, compounding growth driven by the expanding recognition of circRNAs as functionally significant regulatory molecules rather than splicing artifacts, their exceptional stability making them ideal liquid biopsy biomarker candidates, and the emerging circRNA therapeutic pipeline.
The structural biology is elegantly simple yet analytically profound. CircRNAs are formed through back-splicing, a non-canonical splicing process that joins a downstream splice donor to an upstream splice acceptor, creating covalently closed loop structures lacking free 5′ and 3′ termini. This circular conformation confers extraordinary resistance to exonucleases that rapidly degrade linear transcripts, resulting in circRNA half-lives exceeding 48 hours compared to less than 2 hours for typical mRNAs. The analytical consequence is that circRNAs can be detected in accessible biofluids—blood, urine, cerebrospinal fluid—long after their linear counterparts have degraded beyond detection, a property of profound diagnostic significance.
Product Definition: Specialized High-Throughput Sequencing with Enzymatic Enrichment
CircRNA Sequencing Service is a specialized high-throughput sequencing solution designed to identify and analyze circular RNAs (circRNAs), a class of non-coding RNAs with covalently closed loop structures formed by back-splicing. Lacking poly-A tails and exhibiting high stability, circRNAs are abundant in eukaryotic transcriptomes and play significant roles in gene regulation and disease development. This service typically involves pre-treatment steps such as rRNA depletion and RNase R digestion to enrich circRNAs, followed by sequencing using Illumina or long-read platforms. CircRNA sequencing is widely applied in oncology, neurodegenerative diseases, cardiovascular research, and stem cell studies, offering insights into novel biomarkers and molecular mechanisms, and serving as a crucial tool in non-coding RNA research and translational medicine.
The analytical workflow is distinguished from standard RNA sequencing by the essential RNase R enrichment step. Because circRNAs represent a small fraction of total cellular RNA and lack poly-A tails—precluding their capture by standard oligo-dT selection methods—their detection requires specific enrichment strategies. RNase R, a 3′-to-5′ exoribonuclease, preferentially digests linear RNA molecules while sparing circular species lacking accessible termini. The enriched circRNA fraction is then subjected to strand-specific library preparation and deep sequencing. Bioinformatic analysis faces the unique challenge of identifying back-splice junctions—the sequence signatures where upstream and downstream exons are covalently joined in reverse order—distinguishing these circular species from linear transcripts and trans-splicing artifacts.
Technology Segmentation: Tissue, Cell Line, and Emerging Biofluid Applications
The CircRNA Sequencing Service market is segmented by sample type into Tissue Sample, Cell Line Sample, and Others. Tissue samples represent the dominant segment, driven by the extensive biobanks of tumor and matched normal tissues that serve as the primary discovery substrate for circRNA biomarker studies. Cell line samples serve pharmaceutical discovery programs investigating circRNA function in drug response and resistance.
The most strategically significant emerging category within “Others” is biofluid-derived circRNA sequencing. Because circRNAs resist degradation, they can be isolated and sequenced from plasma, serum, urine, and cerebrospinal fluid—samples that would yield extensively degraded RNA unsuitable for standard transcriptome analysis. This property positions circRNA sequencing as a uniquely powerful tool for liquid biopsy development.
Application Landscape: Oncology Research Dominates with Therapeutic Applications Emerging
The application segmentation spans Oncology Research, Immunology Research, and Others. Oncology research represents the dominant application, driven by extensive investigation of circRNA dysregulation in cancer. Specific circRNAs have been demonstrated to function as oncogenes by sponging tumor-suppressive miRNAs, as tumor suppressors by sequestering oncogenic proteins, and as translational templates producing peptides with biological function—fundamentally expanding the functional repertoire attributed to non-coding RNAs.
Immunology research represents a growing application segment, with circRNAs demonstrated to regulate immune cell differentiation, activation, and exhaustion. The emerging circRNA therapeutic pipeline—including engineered circRNA vaccines with enhanced stability relative to linear mRNA—is creating demand for circRNA sequencing services supporting therapeutic characterization.
Competitive Landscape: Global Genomic Service Providers and RNA Specialists
Key market participants profiled include Novogene, Eurofins Scientific, CD Genomics, BGI, Arraystar, BioVenic, Creative Biogene, LC Sciences, BMKGENE, Omics Drive, Mtoz Biolabs, GenScript, Personalbio, and GeneCopoeia. The competitive landscape features global genomic service providers offering circRNA sequencing as part of comprehensive non-coding RNA analysis portfolios, alongside specialized providers differentiating through circRNA-specific expertise and proprietary bioinformatic pipelines.
Industry Challenge: Analytical Complexity, Long-Read Sequencing, and Standardization
The defining analytical challenge is the accurate identification and quantification of circRNAs. The back-splice junction that defines a circRNA represents a sequence rearrangement relative to the reference genome, requiring specialized alignment algorithms. The 2025 U.S. tariff adjustments on imported sequencing reagents and laboratory consumables have introduced supply chain considerations. The integration of long-read sequencing platforms for circRNA analysis represents a significant technology development: long reads spanning full circRNA structures can unambiguously identify back-splice junctions and resolve complex alternative circularization patterns without the computational inference required by short-read approaches.
Exclusive Observation: The Biomarker Discovery Versus Therapeutic Development Service Bifurcation
The circRNA sequencing service market is segmenting into two distinct application domains with divergent requirements. Biomarker discovery services—supporting academic and diagnostic company programs—prioritize comprehensive circRNA profiling, statistical rigor for differential expression analysis, and validation-ready candidate lists. Therapeutic development services—supporting engineered circRNA characterization—require full-length sequencing confirmation of circularization junctions, absence of linear byproducts, and sequence integrity verification. These distinct requirements are creating separate service product lines with different pricing structures and competitive dynamics.
Strategic Outlook Through 2032
The circRNA sequencing service market’s trajectory toward USD 1,068 million by 2032 is underpinned by the expanding recognition of circRNAs as functionally important regulatory molecules, their exceptional stability as biomarker candidates, and the emerging engineered circRNA therapeutic pipeline. For translational researchers and pharmaceutical executives, circRNA sequencing represents an essential discovery and characterization tool at the intersection of non-coding RNA biology, liquid biopsy diagnostics, and next-generation RNA therapeutics.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
